Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Changxuan You, Yi‐Long Wu et al.|The Lancet Oncology|2011Cited by 4.1k
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)C. Zhou, Changxuan You, Yi‐Long Wu et al.|Annals of Oncology|2015Cited by 467
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 TrialShengxiang Ren, Caicun Zhou, Jianhua Chen et al.|Journal of Thoracic Oncology|2021Cited by 311
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinibY. Wang, Fred R. Hirsch, Megan M. Tu et al.|Annals of Oncology|2018Cited by 217
Early detection of lung cancer by using an autoantibody panel in Chinese populationShengxiang Ren, Fred R. Hirsch, Shucai Zhang et al.|OncoImmunology|2017Cited by 203